FRI-221-Management of drug-drug interactions in chronic hepatitis C patients treated with second generation direct acting antivirals in Belgium
Stefan BourgeoisJean‐Pierre MulkayMike CoolVerhelst XavierGeert RobaeysLuc LasserVéronique LefebvreIsabelle ColleChristophe Van SteenkisteJochen DecaesteckerStéphanie CoulonKatrien VenkenThomas Vanwolleghem
Metrics
Topics
Related Documents
4CPS-095 Drug-drug interactions among hepatitis c patients treated with direct-acting antivirals
Blanca Rodríguez VargasE Matilla GarcíaC Apezteguía FernándezMP Bautista SanzL Esteban del HoyoI Santaolalla GarcíaR Moreno Diaz
The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug‐drug interactions
Elise J. SmoldersFloor A. C. BerdenClara TMM de KanterWietske KievitJoost P.H. DrenthDavid M. Burger
Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
Po‐Yao HsuYu‐Ju WeiJia‐Jung LeeSheng‐Wen NiuJiun‐Chi HuangCheng‐Ting HsuTyng‐Yuan JangMing‐Lun YehChing‐I HuangPo‐Cheng LiangYi‐Hung LinMing‐Yen HsiehMeng‐Hsuan HsiehSzu‐Chia ChenChia‐Yen DaiZu‐Yau LinShinn‐Cherng ChenJee‐Fu HuangJer‐Ming ChangShang‐Jyh HwangWan‐Long ChuangChung‐Feng HuangYi‐Wen ChiuMing‐Lung Yu
Reduced work absenteeism in patients with hepatitis C treated with second‐generation direct‐acting antivirals
Peter LindgrenSofia LöfvendahlGunnar BrådvikOla Weiland